Atlas Trials

Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

Clinical trial NCT00369226 · COMPLETED

Trial details

NCT number
NCT00369226
Sponsor
Dana-Farber Cancer Institute
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hematologic Malignancies
Start date
2006-08-01
Primary completion
2010-07-01
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.